Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Boisgerault, Nicolas ^a,b,c   Guillerme, Jean Baptiste ^a,b,c   Pouliquen, Daniel ^a,b,c   Mesel Lemoine, Mariana ^d   Achard, Carole ^a,b,c   Combredet, Chantal ^d   Fonteneau, Jean François ^a,b,c   Tangy, Frédéric ^d   Grégoire, Marc ^a,b,c  

^a UMR892   (France)

^b UMR 6299   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; ENHANCED GREEN FLUORESCENT PROTEIN; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC VIRUS; SCHWARZ LIVE ATTENUATED VACCINAL STRAIN OF MEASLES VIRUS; UNCLASSIFIED DRUG; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; COLORECTAL TUMOR; LUNG TUMOR; MEASLES; MEASLES VIRUS; ONCOLYTIC VIROTHERAPY; PATHOGENICITY; PATHOLOGY; TUMOR CELL LINE; VIROLOGY; XENOGRAFT;

MEASLES VIRUS; MUS MUSCULUS;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MICE; ONCOLYTIC VIROTHERAPY; TRANSPLANTATION, HETEROLOGOUS; VACCINES, ATTENUATED;

EID: 84876519766     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/387362     Document Type: Article

References (48)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Beljanski V., Hiscott J., The use of oncolytic viruses to overcome lung cancer drug resistance. Current Opinion in Virology 2012 2 5 629 635
3. Miyamoto S., Inoue H., Nakamura T., Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Research 2012 72 10 2609 2621 10.1158/0008-5472.CAN-11- 3185
4. Stephenson K. B., Barra N. G., Davies E., Ashkar A. A., Lichty B. D., Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Therapy 2012 19 4 238 246
5. Boisgerault N., Tangy F., Gregoire M., New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy 2010 2 2 185 199 2-s2.0-77953460809 10.2217/imt.10.6
6. Gauvrit A., Brandler S., Sapede-Peroz C., Boisgerault N., Tangy F., Gregoire M., Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Research 2008 68 12 4882 4892 2-s2.0-49649111732 10.1158/0008-5472.CAN-07-6265
7. Lech P. J., Russell S. J., Use of attenuated paramyxoviruses for cancer therapy. Expert Review of Vaccines 2010 9 11 1275 1302 2-s2.0-78649391503 10.1586/erv.10.124
8. Dorig R. E., Marcil A., Chopra A., Richardson C. D., The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993 75 2 295 305 2-s2.0-0027426010 10.1016/0092-8674(93)80071-L (Pubitemid 23320293)
9. Naniche D., Varior-Krishnan G., Cervoni F., Wild T. F., Rossi B., Rabourdin- Combe C., Gerlier D., Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. Journal of Virology 1993 67 10 6025 6032 2-s2.0-0027184631 (Pubitemid 23277513)
10. Fishelson Z., Donin N., Zell S., Schultz S., Kirschfink M., Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Molecular Immunology 2003 40 2-4 109 123 2-s2.0-0041563779 10.1016/S0161-5890(03)00112-3 (Pubitemid 36959821)
11. Guillerme J., Boisgerault N., Roulois D., Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoïd dendritic cells. Clinical Cancer Research. In press
12. Heinzerling L., Künzi V., Oberholzer P. A., Kündig T., Naim H., Dummer R., Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005 106 7 2287 2294 2-s2.0-27144511701 10.1182/blood-2004-11-4558 (Pubitemid 41510798)
13. Galanis E., Hartmann L. C., Cliby W. A., Long H. J., Peethambaram P. P., Barrette B. A., Kaur J. S., Haluska P. J., Aderca I., Zman P. J., Sloan J. A., Keeney G., Atherton P. J., Podratz K. C., Dowdy S. C., Stanhope C. R., Wilson T. O., Federspiel M. J., Peng K. W., Russell S. J., Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research 2010 70 3 875 882 2-s2.0-76249123546 10.1158/0008-5472.CAN-09-2762
14. Noyce R. S., Bondre D. G., Ha M. N., Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathogens 2011 7 8 e1002240
15. Shirogane Y., Takeda M., Tahara M., Ikegame S., Nakamura T., Yanagi Y., Epithelial-mesenchymal transition abolishes the susceptibility of polarized epithelial cell lines to measles virus. Journal of Biological Chemistry 2010 285 27 20882 20890 2-s2.0-77954224542 10.1074/jbc.M110.102590
16. Hoffmann D., Bangen J. M., Bayer W., Wildner O., Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Therapy 2006 13 21 1534 1544 2-s2.0-33750028789 10.1038/sj.gt.3302806 (Pubitemid 44567150)
17. Jing Y., Tong C., Zhang J., Nakamura T., Iankov I., Russell S. J., Merchan J. R., Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Research 2009 69 4 1459 1468 2-s2.0-60549116916 10.1158/0008-5472.CAN-08-2628
18. Gueugnon F., Leclercq S., Blanquart C., Sagan C., Cellerin L., Padieu M., Perigaud C., Scherpereel A., Gregoire M., Identification of novel markers for the diagnosis of malignant pleural mesothelioma. American Journal of Pathology 2011 178 3 1033 1042 2-s2.0-79952766032 10.1016/j.ajpath.2010.12.014
19. Combredet C., Labrousse V., Mollet L., Lorin C., Delebecque F., Hurtrel B., McClure H., Feinberg M. B., Brahic M., Tangy F., A Molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. Journal of Virology 2003 77 21 11546 11554 2-s2.0-10744222209 10.1128/JVI.77.21.11546-11554.2003 (Pubitemid 37271653)
20. Muhlebach M. D., Mateo M., Sinn P. L., Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011 480 7378 530 533
21. Welstead G. G., Iorio C., Draker R., Bayani J., Squire J., Vongpunsawad S., Cattaneo R., Richardson C. D., Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2005 102 45 16415 16420 2-s2.0-28044464983 10.1073/pnas.0505945102 (Pubitemid 41688928)
22. Racaniello V., Virology. An exit strategy for measles virus. Science 2011 334 6063 1650 1651
23. Esolen L. M., Park S. W., Hardwick J. M., Griffin D. E., Apoptosis as a cause of death in measles virus-infected cells. Journal of Virology 1995 69 6 3955 3958 2-s2.0-0029008588
24. Bareschino M. A., Schettino C., Rossi A., Treatment of advanced non small cell lung cancer. Journal of Thoracic Disease 2011 3 2 122 133 10.3978/j.issn.2072-1439.2010.12.08
25. Leong S., Messersmith W. A., Tan A. C., Eckhardt S. G., Novel agents in the treatment of metastatic colorectal cancer. Cancer Journal 2010 16 3 273 282 2-s2.0-77953648749 10.1097/PPO.0b013e3181e076c5
26. Grote D., Russell S. J., Cornu T. I., Cattaneo R., Vile R., Poland G. A., Fielding A. K., Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001 97 12 3746 3754 2-s2.0-0035877990 10.1182/blood.V97.12.3746
27. Phuong L. K., Allen C., Peng K. W., Giannini C., Greiner S., TenEyck C. J., Mishra P. K., Macura S. I., Russell S. J., Galanis E. C., Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Research 2003 63 10 2462 2469 2-s2.0-0037843576 (Pubitemid 36605184)
28. Peng K. W., Ahmann G. J., Pham L., Greipp P. R., Cattaneo R., Russell S. J., Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001 98 7 2002 2007 2-s2.0-0035496901 10.1182/blood.V98.7.2002
29. Peng K. W., TenEyck C. J., Galanis E., Kalli K. R., Hartmann L. C., Russell S. J., Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Research 2002 62 16 4656 4662 2-s2.0-0037102288
30. McDonald C. J., Erlichman C., Ingle J. N., Rosales G. A., Allen C., Greiner S. M., Harvey M. E., Zollman P. J., Russell S. J., Galanis E., A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Research and Treatment 2006 99 2 177 184 2-s2.0-33747605533 10.1007/s10549-006-9200-5 (Pubitemid 44268265)
31. Msaouel P., Iankov I. D., Allen C., Morris J. C., Von Messling V., Cattaneo R., Koutsilieris M., Russell S. J., Galanis E., Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009 69 1 82 91 2-s2.0-58149345608 10.1002/pros.20857
32. Patel B., Dey A., Ghorani E., Kumar S., Malam Y., Rai L., Steele A. J., Thomson J., Wickremasinghe R. G., Zhang Y., Castleton A. Z., Fielding A. K., Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. Molecular Therapy 2011 19 6 1034 1040 2-s2.0-79957909618 10.1038/mt.2011.44
33. Donnelly O. G., Errington-Mais F., Steele L., Measles virus causes immunogenic cell death in human melanoma. Gene Therapy 2011 20 1 7 15
34. Kreuzaler P., Watson C. J., Killing a cancer: what are the alternatives? Nature Reviews Cancer 201212 6 411 424
35. Liu T. C., Kirn D., Viruses with deletions in antiapoptotic genes as potential oncolytic agents. Oncogene 2005 24 40 6069 6079 2-s2.0-26944474044 10.1038/sj.onc.1208734 (Pubitemid 43080057)
36. Nguyen T. L. A., Tumilasci V. F., Singhroy D., Arguello M., Hiscott J., The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cellular Microbiology 2009 11 6 889 897 2-s2.0-65549090518 10.1111/j.1462-5822.2009.01317.x
37. Nguyên T. L. A., Abdelbary H., Arguello M., Breitbach C., Leveille S., Diallo J. S., Yasmeen A., Bismar T. A., Kirn D., Falls T., Snoulten V. E., Vanderhyden B. C., Werier J., Atkins H., Vähä-Koskela M. J. V., Stojdl D. F., Bell J. C., Hiscott J., Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 39 14981 14986 2-s2.0-54449089024 10.1073/pnas.0803988105
38. Otsuki A., Patel A., Kasai K., Suzuki M., Kurozumi K., Chiocca E. A., Saeki Y., Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Molecular Therapy 2008 16 9 1546 1555 2-s2.0-50549097330 10.1038/mt.2008.155
39. Dai M. H., Zamarin D., Gao S. P., Chou T. C., Gonzalez L., Lin S. F., Fong Y., Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. British Journal of Surgery 2010 97 9 1385 1394 2-s2.0-77956420469 10.1002/bjs.7124
40. Kuroda S., Fujiwara T., Shirakawa Y., Yamasaki Y., Yano S., Uno F., Tazawa H., Hashimoto Y., Watanabe Y., Noma K., Urata Y., Kagawa S., Fujiwara T., Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Research 2010 70 22 9339 9348 2-s2.0-78549274429 10.1158/0008-5472.CAN-10-2333
41. Errington F., Steele L., Prestwich R., Harrington K. J., Pandha H. S., Vidal L., De Bono J., Selby P., Coffey M., Vile R., Melcher A., Reovirus activates human dendritic cells to promote innate antitumor immunity. Journal of Immunology 2008 180 9 6018 6026 2-s2.0-44449091136
42. Fridlender Z. G., Sun J., Singhal S., Kapoor V., Cheng G., Suzuki E., Albelda S. M., Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Molecular Therapy 2010 18 11 1947 1959 2-s2.0-78049479930 10.1038/mt.2010.159
43. Iankov I. D., Allen C., Federspiel M. J., Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Molecular Therapy 2012 20 6 1139 1147
44. Wongthida P., Diaz R. M., Galivo F., Kottke T., Thompson J., Melcher A., Vile R., VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Molecular Therapy 2011 19 1 150 158 2-s2.0-78650861433 10.1038/mt.2010.225
45. Gujar S. A., Marcato P., Pan D., Lee P. W. K., Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Molecular Cancer Therapeutics 2010 9 11 2924 2933 2-s2.0-78649661117 10.1158/1535-7163.MCT-10-0590
46. Prestwich R. J., Ilett E. J., Errington F., Diaz R. M., Steele L. P., Kottke T., Thompson J., Galivo F., Harrington K. J., Pandha H. S., Selby P. J., Vile R. G., Melcher A. A., Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clinical Cancer Research 2009 15 13 4374 4381 2-s2.0-67650375869 10.1158/1078-0432.CCR-09-0334
47. Ungerechts G., Springfeld C., Frenzke M. E., Lampe J., Parker W. B., Sorscher E. J., Cattaneo R., An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Molecular Therapy 2007 15 11 1991 1997 2-s2.0-35549009347 10.1038/sj.mt.6300291 (Pubitemid 350011739)
48. Anderson B. D., Nakamura T., Russell S. J., Peng K. W., High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Research 2004 64 14 4919 4926 2-s2.0-3142745262 10.1158/0008-5472.CAN-04-0884 (Pubitemid 38924538)